JUBLIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUBLIA (JUBLIA).
Efinaconazole inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Hepatic metabolism via CYP3A4 and CYP2C19, with minor contribution from CYP2C9 and CYP2C8. |
| Excretion | Primarily fecal (unchanged drug and metabolites); renal elimination is negligible (<1% as unchanged drug in urine). |
| Half-life | Terminal elimination half-life is approximately 72 hours (range 48–96 hours) after topical application, supporting once-weekly dosing. |
| Protein binding | Efinaconazole is >99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution is approximately 2.5 L/kg, indicating extensive distribution into tissues, including nails. |
| Bioavailability | Bioavailability after topical application to nails is negligible systemically (plasma concentrations are low, <0.5 ng/mL). No oral formulation exists. |
| Onset of Action | Onset of clinical improvement (visible nail growth) typically occurs after 4–8 weeks of weekly application; complete cure requires regrowth of healthy nail (48–52 weeks). |
| Duration of Action | Drug persists at the site of action for at least 7 days after a single application, enabling weekly dosing. Therapeutic effect continues throughout treatment course until nail replacement is complete. |
| Molecular Weight | 540.6 |
Apply a thin layer of tavaborole 5% solution to the affected toenails once daily for 48 weeks.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required in patients with renal impairment. Drug not significantly eliminated renally. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy have not been established in pediatric patients below 18 years of age; thus, not recommended. |
| Geriatric use | No specific dose adjustments are recommended for elderly patients, but consider potential for concurrent comorbidities and medication use. |
| 1st trimester | Insufficient human data; animal studies show no risk; use only if clearly needed. |
| 2nd trimester | Insufficient human data; animal studies show no risk; use only if clearly needed. |
| 3rd trimester | Insufficient human data; animal studies show no risk; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for JUBLIA (JUBLIA).
| Placental transfer | Unknown; molecular weight suggests minimal transfer, but no human studies available. |
| Breastfeeding | Not recommended during breastfeeding due to potential systemic absorption and lack of safety data. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to efinaconazole or any excipient
| Precautions | Local irritation (burning, stinging, itching) at application site, Avoid contact with eyes and mucous membranes, Not for ophthalmic, oral, or intravaginal use |
| Food/Dietary | No clinically relevant food interactions have been identified as JUBLIA is applied topically with negligible systemic absorption. |
| Clinical Pearls | JUBLIA (efinaconazole 10% topical solution) is a triazole antifungal indicated for onychomycosis. It has high nail penetration and low keratin binding, allowing effective delivery through the nail plate. Avoid concurrent use with other topical antifungal agents on the same nail. Treatment duration is 48 weeks; clinical improvement may be seen after 6 months. Not for ocular or oral use. |
Loading safety data…
| L3 - Limited Data |
| Teratogenic Risk | JUBLIA (efinaconazole) is a topical triazole antifungal. Based on animal studies and limited human data, systemic absorption is minimal (<1%) following topical application. In animal reproduction studies, no evidence of fetal harm was observed at systemic exposures up to 116 times the human exposure at the maximum recommended human dose (MRHD). However, there are no adequate and well-controlled studies in pregnant women. Because systemic absorption is negligible, the risk of teratogenicity is considered low, but as a precaution, use during pregnancy only if clearly needed. No specific fetal risks have been identified for any trimester. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care. Because systemic absorption is minimal, maternal serum levels are not clinically significant. No fetal monitoring is indicated. |
| Fertility Effects | No fertility studies have been conducted specifically with efinaconazole. Animal studies with other triazole antifungals have shown some effects on fertility at high systemic doses, but given the negligible systemic absorption of topical efinaconazole, no significant impact on human fertility is expected. |
| Patient Advice | Apply to affected toenails once daily for 48 weeks. · Do not use for fingernail infections unless directed by a physician. · Avoid getting the solution in eyes, mouth, or vagina. · Allow solution to dry completely before covering with socks or shoes. · Do not use nail polish or other cosmetic nail products during treatment. · Continue treatment even if no immediate improvement is seen; full cure may take months. · Wash hands after application unless treating fingernails. · Inform doctor if irritation, rash, or signs of infection occur. |